7.7432

6.14% 0.4432

Anavex Life Sciences Corporation (AVXL)

Overview News Price History Option Chain Financials Why AVXL Down? Discussions Forecast Stock Split

Anavex Life Sciences Corporation stock is traded at $7.7432, with a volume of 1.37M. It is up +6.14% in the last 24 hours and up +38.48% over the past month. Anavex Life Sciences Corp is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system diseases with high unmet need. It analyzes genomic data from clinical studies to identify biomarkers, which are used to select patients that will receive the therapeutic benefit for the treatment of neurodegenerative and neurodevelopmental diseases. Its necessary compound ANAVEX 2-73 is being developed to treat Alzheimer's disease, Parkinson's disease, and potentially other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder. The company's operating segment is into developing novel therapies for the management of CNS diseases.

Previous Close:

$7.30

Open:

$7.22

24h Volume:

1.37M

Relative Volume:

1.75

Market Cap:

$619.01M

Revenue:

Net Income/Loss:

$-43.16M

P/E Ratio:

-11.73

EPS:

-0.66

Net Cash Flow:

$-29.31M

1W Performance:

+35.58%

1M Performance:

+38.48%

6M Performance:

+101.25%

1Y Performance:

+28.28%

1-Day Range:

$7.19

$8.10

1-Week Range:

$5.6214

$8.10

52-Week Range:

$3.25

$10.45

Anavex Life Sciences Corporation Stock (AVXL) Company Profile

Name

Anavex Life Sciences Corporation

Sector

Healthcare (1181)

Industry

Biotechnology (680)

Phone

844-689-3939

Address

630 5TH AVENUE, NEW YORK

Employee

Twitter

@anavexlifesci

Next Earnings Date

2024-11-25

Latest SEC Filings

AVXL's Discussions on Twitter

Anavex Life Sciences Corporation Stock (AVXL) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-06-22	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Jun-23-22	Initiated	Berenberg	Buy
Sep-23-21	Initiated	BTIG Research	Buy
Dec-16-20	Reiterated	H.C. Wainwright	Buy
Sep-28-20	Initiated	Ladenburg Thalmann	Buy
Feb-27-20	Initiated	Cantor Fitzgerald	Overweight
Jun-18-19	Initiated	Janney	Buy
May-16-18	Resumed	Maxim Group	Buy
Mar-08-18	Initiated	ROTH Capital	Buy
Feb-13-18	Reiterated	Maxim Group	Buy
Sep-29-17	Resumed	Noble Financial	Buy
Feb-07-17	Initiated	Noble Financial	Buy
Mar-29-16	Initiated	FBR Capital	Outperform

View All

Anavex Life Sciences Corporation Stock (AVXL) Latest News

Nov 04, 2024

HC Wainwright Reiterates "Buy" Rating for Anavex Life Sciences (NASDAQ:AVXL) - MarketBeat

Nov 04, 2024

Nov 01, 2024

Loss-Making Anavex Life Sciences Corp. (NASDAQ:AVXL) Expected To Breakeven In The Medium-Term - Simply Wall St

Nov 01, 2024

Oct 31, 2024

Anavex's Blarcamesine Achieves Pre-specified Efficacy in Phase IIb/III Alzheimer's Trial: Data Presented at CTAD Conference 2024 - The Manila Times

Oct 31, 2024

Oct 18, 2024

NY Biopharma Shares Promising Clinical Data - Streetwise Reports

Oct 18, 2024

Anavex Life Sciences (NASDAQ:AVXL) Rating Reiterated by HC Wainwright - MarketBeat

Oct 18, 2024

Oct 17, 2024

Anavex Life Sciences Announces Encouraging Preliminary Biomarker Results from Ongoing Phase 2 Study of ANAVEX®3-71 for the Treatment of Schizophrenia - StockTitan

Oct 17, 2024

Oct 15, 2024

Short Interest in Anavex Life Sciences Corp. (NASDAQ:AVXL) Declines By 10.3% - MarketBeat

Oct 15, 2024

Oct 10, 2024

Examining Anavex Life Sciences Corporation (AVXL) stock is warranted - US Post News

Oct 10, 2024

Oct 09, 2024

Anavex Life Sciences Corp (AVXL) Q3 2024 Earnings Call Highlights: Strong Cash Position and ... - Yahoo Finance

Oct 09, 2024

Market Insights: Anavex Life Sciences Corporation (AVXL)’s Notable Drop of -2.42, Closing at 5.24 - The Dwinnex

Oct 09, 2024

Understanding the Risks of Investing in Anavex Life Sciences Corporation (AVXL) - Knox Daily

Oct 09, 2024

Oct 03, 2024

The time has not yet come to remove your chips from the table: Anavex Life Sciences Corporation (AVXL) - SETE News

Oct 03, 2024

Renaissance Technologies LLC Has $1.97 Million Stock Position in Anavex Life Sciences Corp. (NASDAQ:AVXL) - MarketBeat

Oct 03, 2024

Oct 01, 2024

A stock that deserves closer examination: Anavex Life Sciences Corporation (AVXL) - US Post News

Oct 01, 2024